VIRAX BIOLABS GROUP RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHWed, 29 Apr 2026 23:41:25 +0200https://images.finanzen.net/images/finanzen_net_neu.gifVIRAX BIOLABS GROUP RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netVirax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersWed, 03 Dec 2025 13:34:00 +0100https://www.finanzen.net/nachricht/aktien/virax-biolabs-ceo-james-foster-outlines-clinical-progress-and-2026-priorities-in-latest-annual-letter-to-shareholders-15331767

Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series of recent ...

]]>https://www.finanzen.net/nachricht/aktien/virax-biolabs-ceo-james-foster-outlines-clinical-progress-and-2026-priorities-in-latest-annual-letter-to-shareholders-15331767Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection SyndromesMon, 03 Nov 2025 14:29:00 +0100https://www.finanzen.net/nachricht/aktien/virax-biolabs-completes-uk-clinical-recruitment-and-reports-constructive-fda-feedback-for-viraximmune-study-evaluating-t-cell-dysfunction-in-post-acute-infection-syndromes-15176347

LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), ...

]]>https://www.finanzen.net/nachricht/aktien/virax-biolabs-completes-uk-clinical-recruitment-and-reports-constructive-fda-feedback-for-viraximmune-study-evaluating-t-cell-dysfunction-in-post-acute-infection-syndromes-15176347